{"article_id": "ZBH_q4_2020.txt", "article": ["now we 're not going to give too many specifics on 20201 , but he 'll give you some color on what we 're seeing from q4 and , again , the impact we think that 's going to have on 2021 .", "certainly , i am , and on note , we said we 're going to hit between 200 to 300 cumulative placements by the end of 2020 .", "we did realize our 2020 expectations of $ 100 million in gross revenue and almost $ 40 million in net of cannibalization revenue during the year .", "and if i just look at q4 specifically , we grew about 30 % over q3 , again , even with the increased pressures of the pandemic in q4 , so very excited with what we 're able to do with avenir complete .", "and then finally for signature one planner , we demonstrated this again , strong sequential growth with registrations up nearly 25 % in q4 over q3 .", "and we expect utilization to continue to expand significantly in 2021 with really a goal of having more than 50 % of our shoulder procedures using pre-surgical planning .", "in fact , the spin - off transaction that we 're going to do over the next year serves to de-risk if not accelerate our path to that 4 % to 5 % growth rate that we have talked about and our 30 % operating margin profile by the end of 2023 .", "net sales in the fourth quarter were $ 2.085 billion , a reported decrease of 1.9 % and a constant currency decrease of 3.7 % versus 2019 .", "beginning with asia -pacific , the region grew 2 % versus q4 2019 with growth across all three of our largest markets of japan , china and australia / new zealand .", "as expected , the emea region was hardest hit by covid - 19 , decreasing 17.5 % versus 2019 , with all sub-regions in decline .", "lastly , the americas region was about flat , decreasing 0.3 % compared to 2019 , driven by continued covid headwinds in latin america , in tandem with a softening u.s. market .", "turning to our business performance for q4 , the global knee business declined 4.8 % negatively impacted by the ongoing pressures in emea .", "however , the u.s. knee business continued to grow , increasing 1.8 % , and asia - pacific knee business returned to growth , increasing 2.9 % .", "our global hip business decreased 3.4 % , again driven by declines in emea .", "both u.s. hips and apac hips continued their growth trends , increasing 1.4 % and 1.3 % respectively .", "sports , extremity , and trauma sales declined 3.3 % .", "dental , spine and cmft continued to deliver better execution , increasing 0.8 % , and finally , our other category was down 9.3 % .", "moving to the p&l , we reported gaap diluted earnings per share of $ 1.59 and adjusted diluted earnings per share of $ 2.11 .", "on an adjusted basis , with revenue down 3.7 % , earnings per share was down about 10 % driven by a lower operating margin and a higher share count , which more than offset the favorable tax rate in the quarter .", "adjusted gross margin was 71.3 % , sequentially better than q3 , but lower than q4 2019 .", "the q4 adjusted tax rate of 15 % was better than the previous year due to geographic mix of income and certain discrete benefits in the quarter , related to recent audit settlements .", "turning to cash and liquidity in the quarter , free cash flow totaled $ 329 million , higher than the same period in 2019 , driven by better working capital and lower capital expenditures , and we utilized better - than - expected cash flow to pay down $ 250 million of debt ahead of schedule , ending the year with cash and cash equivalents of approximately $ 800 million .", "and in terms of capital allocation , we remain committed to maintaining our investment - grade rating and are planning to pay down an additional $ 500 million of debt in 2021 .", "in terms of the newco financial profile , 2019 and 2020 pro forma revenues totaled approximately $ 1.022 billion and $ 897 million respectively and is supported by a diversified geographic base with real opportunities for enhanced growth and margin expansion .", "zb delivered 2019 and 2020 pro forma revenue of $ 6.96 billion and $ 6.128 billion respectively .", "for post - spin zb , the transaction is expected to deliver an improved growth profile with accretion to our revenue growth of approximately 50 basis points over the course of our five - year strategic planning period .", "we also expect that it will expand our adjusted ebitda and operating margins on a pro forma basis by approximately 125 basis points .", "we remain committed to at least 30 % adjusted operating margins by the end of 2023 , and with this transaction we have the opportunity to accelerate the timing of that goal ."], "summary_gold": "compname announces q4 adj earnings per share of $ 2.11 .<q>q4 adjusted earnings per share $ 2.11 .<q>q4 earnings per share $ 1.59 .<q>q4 sales $ 2.085 billion versus refinitiv ibes estimate of $ 2.08 billion .<q>not providing financial guidance at this time .", "summary_pred": "and we expect utilization to continue to expand significantly in 2021 with really a goal of having more than 50 % of our shoulder procedures using pre-surgical planning .<q>net sales in the fourth quarter were $ 2.085 billion , a reported decrease of 1.9 % and a constant currency decrease of 3.7 % versus 2019 .<q>the q4 adjusted tax rate of 15 % was better than the previous year due to geographic mix of income and certain discrete benefits in the quarter , related to recent audit settlements .<q>we did realize our 2020 expectations of $ 100 million in gross revenue and almost $ 40 million in net of cannibalization revenue during the year .<q>adjusted gross margin was 71.3 % , sequentially better than q3 , but lower than q4 2019 .<q>and then finally for signature one planner , we demonstrated this again , strong sequential growth with registrations up nearly 25 % in q4 over q3 .<q>and if i just look at q4 specifically , we grew about 30 % over q3 , again , even with the increased pressures of the pandemic in q4 , so very excited with what we 're able to do with avenir complete .<q>our global hip business decreased 3.4 % , again driven by declines in emea .<q>in fact , the spin - off transaction that we 're going to do over the next year serves to de-risk if not accelerate our path to that 4 % to 5 % growth rate that we have talked about and our 30 % operating margin profile by the end of 2023 .<q>however , the u.s. knee business continued to grow , increasing 1.8 % , and asia - pacific knee business returned to growth , increasing 2.9 % .<q>sports , extremity , and trauma sales declined 3.3 % .<q>moving to the p&l , we reported gaap diluted earnings per share of $ 1.59 and adjusted diluted earnings per share of $ 2.11 .<q>both u.s. hips and apac hips continued their growth trends , increasing 1.4 % and 1.3 % respectively .<q>lastly , the americas region was about flat , decreasing 0.3 % compared to 2019 , driven by continued covid headwinds in latin america , in tandem with a softening u.s. market .<q>and in terms of capital allocation , we remain committed to maintaining our investment - grade rating and are planning to pay down an additional $ 500 million of debt in 2021 .<q>beginning with asia -pacific , the region grew 2 % versus q4 2019 with growth across all three of our largest markets of japan , china and australia / new zealand .", "len_article": 28, "len_summary_gold": 5, "len_summary_pred": 16, "len_sent_scores": 28}